Effect of aspirin on epithelial-mesenchymal transition, migration and invasion in MCF-7 cell induced by platelets
NIU Hong-ling， HUANG xiao-ping， LIU Xiao-long， LI Xiang-zhi， XIAO Gang， LIU Li-xin
Chinese Journal of Clinical Anatomy ›› 2017, Vol. 35 ›› Issue (2) : 183-187.
Effect of aspirin on epithelial-mesenchymal transition, migration and invasion in MCF-7 cell induced by platelets
Objective To identify the effect of aspirin on epithelial-mesenchymal transition, migration and invasion in MCF-7 cells induced by activated platelets. Methods MCF-7 cells were treated with different concentrations of aspirin, platelets activated with arachidonic acid, and different concentrations of aspirin combined platelets activated with arachidonic acid, respectively. Scratch test and transwell test were used to determine the capacities of migration and invasion. Meanwhile, the expression of E-cadherin and Vimentin which linked to epithelial-mesenchymal transition (EMT) was measured by Western Blot. Results After the intervention of activated platelets, the migration and invasion capabilities of MCF-7 cells were enhanced (P<0.05). The expression of E-cadherin was decreased and Vimentin was increased obviously. After the treatment of low and high concentration aspirin combined with platelets, the migration and invasion capabilities were decreased compared with the group which was treated only with activated platelets(P<0.05). The expression of E-cadherin was elevated and Vimentin was obviouslt reduced. When MCF-7 cells were treated with low concentration (0.5 mmol/l) and high concentration (2.0 mmol/l) of aspirin only,there was no significant difference in the migration and invasion capabilities(P>0.05) compared with the control group without intervention. Meanwhile, Western Blot showed no obvious changes in the expression of E-cadherin and Vimentin (P>0.05). Conclusion Results in vitro experiments indicated that aspirin could inhibit the abilities of epithelial-mesenchymal transition (EMT), migration and invasion in MCF-7 cells through suppressing the activation of platelets.
MCF-7 human breastcancer cells / Aspirin / Platelets activation / Migration / Invasion
[1] Fan L, Kathrin SW, Jun JL, et a1. Breast cancer in China [J]．Lancet Oncol，2014，15(7)：e279-e289．
[2] Felipe Lima J, Nofech-Mozes S, Bayani J, et al. EMT in breast carcinoma—a review[J]. J Clin Med, 2016, 5(7):pii: E65.
[3] Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction[J]．Proc Natl Acad Sci USA,1968,61(1):46-52.
[4] Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement[J].Lancet Oncol, 2009,10(5):501-507.
[5] Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: a summary review to 2007[J]. Recent Results Cancer Res, 2009,181:231-251.
[6] Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long term risk of death due to cancer: analysis of individual patient data from randomised trials[J]. Lancet, 2011, 377(9759):31-41.
[7] Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis[J]. Gastroenterology, 2012,142(3):442-452.
[8] Holmes MD, Chen WY, Li L, et al. Aspirin intake and survival after breast cancer[J]．J Clin Oncol, 2010, 28(9):1467-1472.
[9] Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis[J]．Cancer Cell, 2011, 20(5):576-590.
[10] 孙宝存.病理学[M].北京：北京大学医学出版社，2009:79-85.
[11] Kalluring R, Weinberg RA. The basics of epithelial-mesenchymal transition [J]. J Clin Invest, 2009,119(6):1420-1428.
[12] Onder TT, Gupta PB, Mani SA, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways[J]. Cancer Res, 2008, 68(10): 3645-3654.
[13] Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity[J].Cancer Res, 2009, 69(19):7775-7783.
[14] Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GPIIb/IIIa antagonist XV454[J].Thromb Haemost, 2003, 90(3):549-554.
[15] Bouris P, Skandalis SS, Piperigkou Z, et al. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells[J]. Matrix Biol, 2015,43:42-60.
[16] Wu KK, Liou JY, Cieslik K. Transcriptional control of COX-2 via C/EBPbeta[J]. Arterioscler Thromb Vasc Biol, 2005, 25(4): 679-685.
[17] Patrano C. Aspirin as an antiplatelet drug[J].N Engl J Med, 1994, 330(18):1287-1294.
/
| 〈 |
|
〉 |
